Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye
        • James Bradner
        • Victor Bulto
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Operations
        • Global Biotech Cooperations
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Stories from our Labs
      • Open Source Science
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • Environmental, Social and Governance (ESG) Index
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Learning and Development
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home
  • Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma
    Basel, May 4, 2022 — Novartis announced today that the European Commission (EC) has approved Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. The approval follows a positive opinion in March by the Committee…
    OncologyCell and Gene TherapyCancer
  • Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
    Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the European Commission to approve Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
    OncologyCell and Gene TherapyCancer
  • Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
    Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
    Global Health PartnershipsCell and Gene TherapyCancer
  • Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
    Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.
    OphthalmologyFuture of HealthcareEye CareCell and Gene Therapy
  • Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
    Basel, December 13, 2021 — Novartis today announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. At the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021, Novartis will…
    Reimagine MedicineMedical InnovationsCell and Gene Therapy
  • Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
    Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment. The BELINDA study did not meet its primary endpoint of event-free survival compared to treatment with the…
    Cell and Gene TherapyCancer
  • Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
    Basel, 21. September 2021 — Novartis hat heute die Übernahme von Arctos Medical bekanntgegeben. Das Unternehmen erweitert dadurch sein Portfolio in der Augenheilkunde um das präklinische AAV*-Gentherapieprogramm sowie die entsprechende Technologie von Arctos. Die Übernahme unterstreicht das Engagement von Novartis, Behandlungsmöglichkeiten für…
    OphthalmologyEye CareCell and Gene Therapy
  • Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
    Bâle, le 21 septembre, 2021 — Novartis a annoncé aujourd’hui avoir acquis Arctos Medical, ajoutant à son portefeuille d’ophtalmologie un programme préclinique de thérapie génique AAV basé sur l’optogénétique et la technologie exclusive d’Arctos. Cette acquisition souligne l’engagement de Novartis dans la recherche de traitements pour les patients…
    OphthalmologyEye CareCell and Gene Therapy
  • Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
    Basel, September 21, 2021 — Novartis today announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of…
    OphthalmologyEye CareCell and Gene Therapy
  • Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
    Basel, October 30, 2020 — Novartis today announced the receipt of marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe ("FBRI") to manufacture and supply commercial Kymriah® (tisagenlecleucel) for patients in Japan. This approval makes FBRI the…
    Reimagine MedicineOncologyCell and Gene Therapy
  • Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
    Basel, April 23, 2021 — Novartis today announced plans to initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of Zolgensma® (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) weighing ≥ 8.5 kg and ≤ 21 kg, following a one-time, intravenous (IV) infusion. The new clinical data will supplement…
    Drug DiscoveryChildren's HealthCell and Gene Therapy
  • Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
    Basel, December 9, 2019 – Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications. These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with…
    Targeted TherapyReimagine MedicineCell and Gene TherapyCancer

Pagination

  • 1
  • 2
  • 3
  • › Next page

Novartis

Navigate
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience